Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

A compound represented by Formula 3 as described herein, or a pharmaceutically acceptable salt thereof, and a method of making a Formula 3 compound. In Formula 3: R.sub.1 is hydrogen; and Cy is unsubstituted benzothiazol-6-yl, benzothiazol-5-yl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, or oxodihydrobenzoxazolyl; or substituted benzothiazol-6-yl, benzothiazol-5-yl, indazolyl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, oxodihydrobenzoxazolyl, or oxodihydrobenzoimidazolyl, each of which is substituted with: (i) methyl, ethyl, propyl, butyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, bromo, trifluoroethyl, difluoromethyl, trifluoromethoxy, dimethylcarbamoyl, phenoxy, isopropoxy, methylamino or dimethylamino; or (ii) phenyl, pyridinyl, furanyl, or thiophenyl unsubstituted or substituted with at least one of methyl, fluoro, and dimethylamino. A compound of Formula 4 as described herein, or a pharmaceutically salt thereof.

A compound represented by Formula 3 as described herein, or a pharmaceutically acceptable salt thereof, and a method of making a Formula 3 compound. In Formula 3: R.sub.1 is hydrogen; and Cy is unsubstituted benzothiazol-6-yl, benzothiazol-5-yl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, or oxodihydrobenzoxazolyl; or substituted benzothiazol-6-yl, benzothiazol-5-yl, indazolyl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, oxodihydrobenzoxazolyl, or oxodihydrobenzoimidazolyl, each of which is substituted with: (i) methyl, ethyl, propyl, butyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, bromo, trifluoroethyl, difluoromethyl, trifluoromethoxy, dimethylcarbamoyl, phenoxy, isopropoxy, methylamino or dimethylamino; or (ii) phenyl, pyridinyl, furanyl, or thiophenyl unsubstituted or substituted with at least one of methyl, fluoro, and dimethylamino. A compound of Formula 4 as described herein, or a pharmaceutically salt thereof.